SXSW takes a pulse on what is hot in technology and popular culture for the coming year, and several trends emerged that pharma can begin working with now. Here’s what we saw at SXSW and what you need to know about it.

Did we miss something that will have a major impact on pharma marketing this year? We asked our respondents to write their own questions and answer them.

Renata Maia joins the agency from IPG Health’s award-winning AREA 23.

The COVID-19 pandemic compelled the industry to re-examine the way it conducted clinical trials, engaged with patients, and promoted to HCPs. Companies began to explore decentralized clinical trials, new non-personal promotion strategies, virtual customer engagement strategies, and new ways to engage with the patient — all with an eye toward replacing status quo processes and technologies. The result was the accelerated development of new clinical and commercial technologies and data with the ultimate goal of bringing new therapies to patients faster.

Part III: Leaders in healthcare marketing and communications explain where technology will have the most impact on the industry.

For years digital health platforms have been integral in helping navigate viral outbreaks such as HIV, COVID-19, and monkeypox. Ramin Bastani, CEO of Healthvana – a platform that delivers test results and records (the company just surpassed 50 million records delivered) to get patients on the right track to receive treatment – talks about how such digital health solutions are improving the response to disease outbreaks.

Although artificial intelligence may seem like the great equalizer to humanity’s flawed motivational and cognitive biases, the truth is, even the most advanced AI technologies have biases including race, gender, socioeconomic status, and political identifiers.

VMLY&R’s Walter Geer shares his take on the industry’s progress over the past several decades, and the importance of technology, brand authenticity, patient access and much more.

A Q&A with Wendy Carhart of Real Chemistry

While 90 may not be the new 40, it may become the new 75 or 80 as science, technology and policies converge to leverage the gains from the genomics revolution, which are making precision medicine a clinical reality.